This site is intended for health professionals only

New treatment test for bone disease


A possible milestone in the treatment of hypophosphatasia, a rare and often crippling genetic bone disorder, has been announced by emerging biotech company Enobia Pharma.

It is researching enzyme replacement therapy (ERT) with ENB-0040 to tackle the condition, for which there is as yet no approved treatment.

Under two separate protocols, ENB-0040 will be evaluated in both adults and infants afflicted with hypophosphatasia in Canada and the USA.

“This may well be a milestone in the treatment of hypophosphatasia,” said Michael Whyte, professor of medicine at Washington University School of Medicine. “Studies in a model for hypophosphatasia show ENB-0040 has the potential to greatly enhance the quality of life for patients.”

Under the first protocol, safety, tolerability and pharmacokinetics will be evaluated for one month in an open-label, dose escalation Phase I study of ENB-0040 delivered intravenously and subcutaneously to six adults with hypophosphatasia.

Under the second protocol, similar tests will be evaluated in a six-month open-label study of up to six infants with particularly severe hypophosphatasia.

Enobia boss Robert Heft said: “The initiation of clinical studies brings us closer to the goal of providing drug therapy for hypophosphatasia patients where none currently exists.”

Copyright PA Business 2008

Enobia Pharma

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine